RT Journal Article
SR Electronic
T1 Detection of Alteration in Carotid Artery Volumetry Using Standard-of-care Computed Tomography Surveillance Scans Following Unilateral Radiation Therapy for Early-stage Tonsillar Squamous Cell Carcinoma Survivors: A Cross-Sectional Internally-Matched Carotid Isodose Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.03.24302288
DO 10.1101/2024.02.03.24302288
A1 Koutroumpakis, Efstratios
A1 Naser, Mohamed A.
A1 Mohamed, Abdallah Sherif Radwan
A1 Eraj, Salman A.
A1 Jarre, Andrea
A1 Shiao, Jay C.
A1 Kamal, Mona
A1 Perni, Subha
A1 Phan, Jack P.
A1 Morrison, William H.
A1 Frank, Steven J.
A1 Gunn, G. Brandon
A1 Garden, Adam S.
A1 Deswal, Anita
A1 Abe, Jun-ichi
A1 Rosenthal, David I.
A1 Mouhayar, Elie
A1 Fuller, Clifton D.
YR 2024
UL http://medrxiv.org/content/early/2024/05/16/2024.02.03.24302288.abstract
AB Purpose Radiation induced carotid artery disease (RICAD) is a major cause of morbidity and mortality among survivors of oropharyngeal cancer. This study leveraged standard-of-care CT scans to detect volumetric changes in the carotid arteries of patients receiving unilateral radiotherapy (RT) for early tonsillar cancer, and to determine dose-response relationship between RT and carotid volume changes, which could serve as an early imaging marker of RICAD.Methods and Materials Disease-free cancer survivors (>3 months since therapy and age >18 years) treated with intensity modulated RT for early (T1-2, N0-2b) tonsillar cancer with pre- and post-therapy contrast-enhanced CT scans available were included. Patients treated with definitive surgery, bilateral RT, or additional RT before the post-RT CT scan were excluded. Pre- and post-treatment CTs were registered to the planning CT and dose grid. Isodose lines from treatment plans were projected onto both scans, facilitating the delineation of carotid artery subvolumes in 5 Gy increments (i.e. received 50-55 Gy, 55-60 Gy, etc.). The percent-change in sub-volumes across each dose range was statistically examined using the Wilcoxon rank-sum test.Results Among 46 patients analyzed, 72% received RT alone, 24% induction chemotherapy followed by RT, and 4% concurrent chemoradiation. The median interval from RT completion to the latest, post-RT CT scan was 43 months (IQR 32-57). A decrease in the volume of the irradiated carotid artery was observed in 78% of patients, while there was a statistically significant difference in mean %-change (±SD) between the total irradiated and spared carotid volumes (7.0±9.0 vs. +3.5±7.2, respectively, p<.0001). However, no significant dose-response trend was observed in the carotid artery volume change withing 5 Gy ranges (mean %-changes (±SD) for the 50-55, 55-60, 60-65, and 65-70+ Gy ranges [irradiated minus spared]: −13.1±14.7, −9.8±14.9, −6.9±16.2, −11.7±11.1, respectively). Notably, two patients (4%) had a cerebrovascular accident (CVA), both occurring in patients with a greater decrease in carotid artery volume in the irradiated vs the spared side.Conclusions Our data show that standard-of-care oncologic surveillance CT scans can effectively detect reductions in carotid volume following RT for oropharyngeal cancer. Changes were equivalent between studied dose ranges, denoting no further dose-response effect beyond 50 Gy. The clinical utility of carotid volume changes for risk stratification and CVA prediction warrants further evaluation.Competing Interest StatementEK is supported in part by NIH/NCI 1R01 HL157273 and CPRIT RP200381 both of which are not related to the current work. Dr. Fuller receives related grant, salary, and infrastructure support from MD Anderson Cancer Center via: the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image-guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Image-Driven Biology and Therapy (IDBT) Program (P30CA016672). Dr. Fuller has received unrelated grants/honoraria from Elekta AB, has received travel support from Philips Medical Systems, and has served in an advisory capacity for Siemens Healthineers.Funding StatementSupported by resources from the P30CA016672 Cancer Center Support Grant Image-Driven Biologically Informed Therapy (IDBT) ProgramAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of the University of Texas MD Anderson Cancer Center approved this retrospective protocol and waived the need for a consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.